SMi is proud to present the 3rd Annual Injectable Drug Delivery Conference in London on 2nd and 3rd September 2020.
Part of Europe’s leading Injectable conference series, we will assess innovations in drug product formulation and biologics, innovations in device design, quality management and connectivity for enhanced subcutaneous delivery.
With rapid developments in the parenteral space the injectable drug delivery market is set to reach USD 902.3 billion by 2027, with an increased focus on patient centricity during DDC development, innovations in device development, including and new therapeutic applications including the delivery of siRNA - this year’s event will focus on advances in drug product formulation and innovations of device design and development to aid delivery.
Furthermore, this year’s event will assess the evolving regulatory environment of injectable drug delivery with industry and regulatory representatives presenting updates on current guidelines.
This two-day agenda offers you peer-to-peer networking with Global Product Managers, Device Testing Managers, Senior Device Engineers, Heads of Device Development, Heads of Formulation and Drug Process Development, and many more.
We look forward to welcoming you to the conference in September.
BENEFITS OF ATTENDING:
- DELVE into the latest work in complex formulation for subcutaneous delivery
- BENCHMARK against leading pharma companies working to enhance device design and development
- UNDERSTAND the regulatory environment of the injectables space from leading regulatory and industry advisors
- ENGAGE in industry case studies on design controls, human factors and parenteral formulation
- EXPLORE advances in connectivity and human factors key learnings in two pre-conference workshops